{"id":"W2978507674","doi":"10.1093/annonc/mdz253.094","title":"Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Nivolumab; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003721113,0.002233386,0.003860791,0.0004347033,0.0005047596,0.001308669,0.001125778,0.002453792,0.007018519],"category_scores_gemma":[0.003032671,0.0007514854,0.003293704,0.0005488597,0.001522514,0.001653099,0.0005112382,0.005074174,0.001393395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00123065,"about_ca_system_score_gemma":0.001326071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001128403,"about_ca_topic_score_gemma":0.002324451,"domain_scores_codex":[0.9987383,0.0007030215,0.0000757523,0.0002191334,0.00007443513,0.0001894163],"domain_scores_gemma":[0.9980009,0.0007285945,0.0003736913,0.0001893575,0.0001123845,0.0005950013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9815546,0.003961098,0.0004341337,0.0003556294,0.001181638,0.00002794593,0.0000390932,0.0002939903,0.002089785,0.00007568405,0.0005834664,0.009402814],"study_design_scores_gemma":[0.9378071,0.05913589,0.001189789,0.00002565656,0.0007472494,0.00003283189,0.00001598927,0.000159869,0.0002970306,0.0001377455,0.0004398776,0.00001092639],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.975224,0.01054492,0.001128884,0.001567967,0.001155104,0.003817371,0.002859962,0.0001629882,0.003538713],"genre_scores_gemma":[0.9792628,0.004531287,0.002330838,0.002353763,0.0007204504,0.002971821,0.00398904,0.00006321835,0.003776703],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007018519,"threshold_uncertainty_score":0.02347922,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08317332167414404,"score_gpt":0.3884031649587813,"score_spread":0.3052298432846373,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}